Clinical Trials
729
55 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1850
Active, not recruiting
27
3.7%
Completed
480
65.8%
Enrolling By Invitation
8
1.1%
Not yet recruiting
20
2.7%
Recruiting
92
12.6%
Suspended
1
0.1%
Terminated
64
8.8%
Unknown
1
0.1%
Withdrawn
36
4.9%
No approval data available
- A University of Rochester collaboration is piloting SOPHIE, an AI-powered virtual patient platform, to strengthen dental residents' communication, trust-building, and empathy skills. - The training, organized around the "three E's" of Empower, Empathy, and Explicit, lets residents practice difficult conversations repeatedly in a low-stakes, browser-accessible setting. - Residents reported increased confidence in handling challenging patient conversations, with AI-generated measures suggesting improvements in conversational balance and open-ended questioning. - The study, published in the Journal of Dental Education, brought together Eastman Institute for Oral Health, Computer Science, and the Clinical and Translational Science Institute.
- ARPA-H's PROSPR program is funding seven research teams with up to $144 million over five years to develop interventions that extend healthspan by treating aging as a tractable biological process. - The initiative aims to identify early biomarkers that can serve as surrogate endpoints to demonstrate therapeutic efficacy within one to three years, addressing the challenge of lengthy conventional aging trials. - University of Rochester received up to $22 million to test TPN-101, an HIV drug repurposed to suppress retrotransposon activity and reduce age-related inflammation in a 200-participant clinical trial. - Cambrian BioPharma was awarded up to $30.8 million to advance human trials of a next-generation rapamycin analog targeting mTORC1 signaling for metabolic resilience improvement.
- A large real-world study of nearly 1,400 patients demonstrates that people ages 80 and older with diffuse large B-cell lymphoma can achieve the same cure rates with half-dose chemotherapy as with standard full-dose treatment. - The mini-R-CHOP regimen showed lower rates of treatment discontinuation due to side effects compared to full-dose R-CHOP, while preserving therapeutic effectiveness in elderly patients. - Researchers from the University of Rochester presented findings at the American Society of Hematology annual meeting, validating reduced-dose approaches in community cancer clinics across the United States. - The study supports a new clinical trial combining mini-R-CHOP with immunotherapy drug mosunetzumab for older DLBCL patients, representing continued efforts to optimize treatment for elderly cancer populations.
- Researchers at University of Rochester and Harvard Medical School developed CBD-IN, a nano-micelle formulation that successfully crosses the blood-brain barrier and provides neuropathic pain relief within 30 minutes in mice. - The novel delivery system targets only overactive pain circuits while leaving healthy neurons unaffected, avoiding the motor and cognitive side effects commonly seen with conventional pain medications. - CBD-IN works through a novel mechanism independent of traditional cannabinoid receptors, influencing broader electrical and calcium signaling in nerve cells without causing dependency risks. - The formulation maintained effectiveness through repeated use and delivered significantly higher brain concentrations compared to standard oil-based CBD products.
- Genflow Biosciences has successfully progressed its SIRT6 variant patent application through the European Patent Office's Supplementary Search Report without additional questions, strengthening its intellectual property position. - The company's Japanese patent application for SIRT6 variants has advanced to the national examination phase, expanding protection in a key market with one of the world's most rapidly aging populations. - Genflow's lead compound GF-1002, which delivers a centenarian variant of the SIRT6 gene, is scheduled to begin clinical trials in 2025 for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- PhotoPharmics has enrolled 150 participants in its Light for PD Phase 3 clinical trial, evaluating specialized phototherapy for both motor and non-motor symptoms of Parkinson's disease. - Building on promising Phase 2 results, the innovative light therapy device aims to improve patients' quality of life by targeting circadian function and neurological health. - The study, led by Dr. Ray Dorsey at the University of Rochester, focuses on addressing often-overlooked non-motor symptoms that significantly impact daily life but have limited treatment options.
- Recent data shows significant gender disparity in cancer care, with 31% of women and 21% of men reporting their initial health concerns were not taken seriously by healthcare providers. - Financial barriers continue to impact cancer treatment decisions, with 17% of patients avoiding essential follow-up care due to cost concerns and 69% experiencing treatment delays from prior authorization processes. - Healthcare providers are implementing innovative solutions including telehealth services, nurse navigation programs, and technology integration to improve patient access and reduce administrative burdens in cancer care.
